Related Experiment Video
Updated: Mar 24, 2026
05:55
Author Spotlight: Developing a Rat Model for Weight-Bearing Intervention to Investigate Osteonecrosis of the Femoral Head
Published on: September 27, 2024
1.1K
[An update on glucocorticoid-induced osteoporosis]
Deutsche Medizinische Wochenschrift (1946)
|March 4, 2016
Summary
Glucocorticoid-induced osteoporosis is a common secondary cause of bone fractures, even at low doses. Early diagnosis and treatment are crucial for reducing fracture risk in patients using glucocorticoids.
Area of Science:
- Endocrinology
- Bone Metabolism
- Pharmacology
Context:
- Glucocorticoid-induced osteoporosis (GIOP) is the leading cause of secondary osteoporosis.
- It is a significant factor in osteoporosis among young adults.
- Oral glucocorticoid therapy rapidly increases fracture incidence within three months.
Purpose:
- To discuss the pathophysiology of glucocorticoid-induced osteoporosis.
- To summarize current diagnostic and therapeutic recommendations.
- To present recently updated German guidelines for managing GIOP.
Summary:
- Glucocorticoids, even at low doses (e.g., 2.5 mg prednisone equivalent), elevate fracture risk.
- Pathophysiological mechanisms underlying GIOP are complex.
- Effective diagnostic strategies and therapeutic interventions can mitigate fracture risk.
Impact:
- Highlights the importance of early detection and management of GIOP.
- Provides clinicians with updated guidelines for patient care.
- Aims to reduce the burden of fractures associated with glucocorticoid therapy.
Related Concept Videos
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
614
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
614
01:24Glucagon-like Receptor Agonists
1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
01:29Bone Disorders
7.0K
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
7.0K
01:31Osteoclasts in Bone Remodeling
4.7K
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
4.7K
01:06Oral Hypoglycemic Agents: Glinides
929
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
929
01:15Hypoglycemia and Glucagon
1.3K
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.3K